Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01954043 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors
A Phase 1 study of Cancer, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 23
- Enrollment target
- 6
- Study locations
NCT01954043 is a Phase 1 study of Cancer that has completed, run by GlaxoSmithKline. The registered enrollment target is 23 participants, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 5 states.
The verdict
NCT01954043, a Phase 1 study of Cancer, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 23 participants
- Enrollment target
- 6
- Study locations
Study Summary
The study is being conducted to evaluate the effect of rifampin (a strong CYP3A4 inducer) and rabeprazole (a pH elevating agent) on the PK of dabrafenib (a CYP3A4/CYP2C8 substrate). The study will be conducted in subjects with BRAF V600 mutation-positive tumors. Data collected from this study will be used to inform recommendations regarding use of concomitant medications with dabrafenib and future clinical pharmacologic evaluation of dabrafenib.
Conditions Studied
Interventions
- DRUG Dabrafenib 150 mg twice a day (BID)
- DRUG Rabeprazole 40 mg once daily (OD)
- DRUG Rifampin 600 mg OD
Study Locations (6)
Victoria
- GSK Investigational Site - Heidelberg
- GSK Investigational Site - Melbourne
Arizona
- GSK Investigational Site - Goodyear
Texas
- GSK Investigational Site - Dallas
Washington
- GSK Investigational Site - Tacoma
Other
- GSK Investigational Site - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2013-12-20 |
| Est. Completion | 2016-02-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01954043
The ClinicalTrials.gov registry entry for NCT01954043 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,491-participant average among 615 other Cancer trials with a reported enrollment target (99% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer appearing as the primary indexed condition, and to 3 interventions - of which Dabrafenib 150 mg twice a day (BID) is the first listed.
NCT01954043 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Victoria, Arizona, Texas.
Frequently Asked Questions
What is clinical trial NCT01954043 about?
NCT01954043 is a clinical study titled "A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors". The study is being conducted to evaluate the effect of rifampin (a strong CYP3A4 inducer) and rabeprazole (a pH elevating agent) on the PK of dabrafenib (a CYP3A4/CYP2C8 substrate). The study will be conducted in subjects with BRAF V600 mutation-positive tumors. Data collected from this study will b...
What is the current status of trial NCT01954043?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 23 participants. The study started on 2013-12-20. Estimated completion is 2016-02-29.
What conditions does trial NCT01954043 study?
This clinical trial studies the following conditions: Cancer.
What interventions are being tested in trial NCT01954043?
The interventions under investigation include: Dabrafenib 150 mg twice a day (BID) (DRUG), Rabeprazole 40 mg once daily (OD) (DRUG), Rifampin 600 mg OD (DRUG).
Who is sponsoring clinical trial NCT01954043?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01954043 being conducted?
This trial has 6 study locations across Arizona, Texas, Washington, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RECRUITING · Phase 1
-
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Impact of Daily Oral Cannabis Doses in Patients With Cancer
RECRUITING · Phase 1
-
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.